Skip to main content
SpringerLink
Log in

Review of Novel Immunotherapeutic Strategies for MS

  • Chapter
Immune Regulation and Immunotherapy in Autoimmune Disease

  • 747 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103(9):1243–1252.

    Article  PubMed  CAS  Google Scholar 

  • Abrams, J. R., Kelley, S. L., Hayes, E., et al. (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192(5):681–694.

    Article  PubMed  CAS  Google Scholar 

  • Ahrens, N., Salama, A., Haas, J. (2001). Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J. Neurol. 248(8):713–714.

    Article  PubMed  CAS  Google Scholar 

  • Aktas, O., Waiczies, S., Smorodchenko, A., et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 17;197(6):725–733.

    Article  CAS  Google Scholar 

  • Alegre, M. L., Sattar, H. A., Herold, K. C., et al. (1994) Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 57(12):1786–1794.

    PubMed  CAS  Google Scholar 

  • Aloisi, F., Penna, G., Polazzi, E., et al. (1999) CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. J. Immunol. 162(3):1384–1391.

    PubMed  CAS  Google Scholar 

  • Andersen, O., Lycke, J., Tollesson, P. O. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47:895–900.

    PubMed  CAS  Google Scholar 

  • Anderson, D. E., Sharpe, A. H., Hafler, D. A. (1999) The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr. Opin. Immunol. 11(6):677–683.

    Article  PubMed  CAS  Google Scholar 

  • Anderson, D. E., Bieganowska, K. D., Bar-Or, A., et al. (2000) Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat. Med. 6(2):211–214.

    Article  PubMed  CAS  Google Scholar 

  • Anonymous. (2004) Drugs RD 5(6):363–367.

    Article  Google Scholar 

  • Archelos, J. J., Hartung, H. P. (2000) Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 23:317–327.

    Article  PubMed  CAS  Google Scholar 

  • Archelos, J. J., Previtali, S. C., Hartung, H. P. (1999) The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22(1):30–38.

    Article  PubMed  CAS  Google Scholar 

  • Archelos, J. J., Storch, M. K., Hartung, H. P. (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47(6):694–706.

    Article  PubMed  CAS  Google Scholar 

  • Arroyo, A. G., Yang, J. T., Rayburn, H., Hynes, R. O. (1996) Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85(7):997–1008.

    Article  PubMed  CAS  Google Scholar 

  • Babbe H., Roers A. Waisman A. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 1192:393–404.

    Article  Google Scholar 

  • Baecher-Allan, C., Hafler, D. A. (2004) Suppressor T cells in human diseases. J. Exp. Med. 200(3):273–276.

    Article  PubMed  CAS  Google Scholar 

  • Baggiolini, M. (1998) Chemokines and leukocyte traffic. Nature 392(6676):565–568.

    Article  PubMed  CAS  Google Scholar 

  • Bar-Or, A., Antel, J., Bodner, C. A. (2006) Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Neurology 66(Suppl.):A62.

    Google Scholar 

  • Beggiolin, G., Crippa, L., Menta, E., et al. (2001) Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87(6):407–416.

    PubMed  CAS  Google Scholar 

  • Benoist, C., Mathis, D. (2001) Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2:797–801.

    Article  PubMed  CAS  Google Scholar 

  • Bernitsas, E., Wei, W., Mikol, D. D. (2006) Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann. Neurol. 59(1):206–209.

    Article  PubMed  CAS  Google Scholar 

  • Beutler, E. (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340(8825):952–956.

    Article  PubMed  CAS  Google Scholar 

  • Beutler, E., Sipe, J. C., Romine, J. S., et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. U S A 93(4):1716–1720.

    Article  PubMed  CAS  Google Scholar 

  • Bielekova, B., Goodwin, B., Richert, N., et al. (2000a) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6(10):1167–1175.

    Article  PubMed  CAS  Google Scholar 

  • Bielekova, B., Lincoln, A., McFarland, H., Martin, R. (2000b) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 164(2):1117–1124.

    PubMed  CAS  Google Scholar 

  • Bielekova, B., Richert, N., Howard, T., et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U S A. 101(23):8705–8708.

    Article  PubMed  CAS  Google Scholar 

  • Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., et al. (2006) Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R{alpha}-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U S A. 103(15):5941–5946.

    Article  PubMed  CAS  Google Scholar 

  • Birnbaum, G., Altafullah, I. (2005) Neurology 64(Suppl. 1):A385, P06.158.

    Google Scholar 

  • Bisikirska, B., Colgan, J., Luban, J., et al. (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115(10):2904–2913.

    Article  PubMed  CAS  Google Scholar 

  • Bjartmar, C., Trapp, B. D. (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14:271–278.

    Article  PubMed  CAS  Google Scholar 

  • Bluestone, J. A., St. Clair, E. W., Turka, L. A. (2006) CTLA4Ig: bridging the basic immunology with clinical application. Immunit. 24(3):233–238.

    Article  CAS  Google Scholar 

  • Bowen, J. D., Petersdorf, S. H., Richards, T. L., et al. (1998) Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin. Pharmacol. Ther. 64(3):339–346.

    Article  PubMed  CAS  Google Scholar 

  • Brassat, D., Recher, C., Waubant, E., et al. (2002) Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 59(6):954–955.

    PubMed  CAS  Google Scholar 

  • Brinkmann, V., Davis, M. D., Heise, C. E., et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277(24):21453–21457.

    Article  PubMed  CAS  Google Scholar 

  • Bruck, W., Neubert, K., Berger, T., Weber, J. R. (2001) Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination—possible markers for an antibody-mediated process. Mult. Scler. 7(3):173–177.

    PubMed  CAS  Google Scholar 

  • Brundula, V., Rewcastle, N. B., Metz, L. M., et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125(Pt 6):1297–1308.

    Article  PubMed  Google Scholar 

  • Brunmark, C., Runstrom, A., Ohlsson, L., et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130(1–2):163–172.

    Article  PubMed  CAS  Google Scholar 

  • Budde K., Schmouder R. L., Brunkhorst R., et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13(4):1073–1083.

    PubMed  CAS  Google Scholar 

  • Calabresi, P. A., Wilterdink, J. L., Rogg, J. M., et al. (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58(2):314–317.

    PubMed  CAS  Google Scholar 

  • Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337(8739):441–446.

    Google Scholar 

  • Carreno, B. M., Collins, M. (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29–53.

    Article  PubMed  CAS  Google Scholar 

  • Cavaletti, G., Cavalletti, E., Crippa, L., et al. (2004) Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. 151(1–2):55–65.

    Article  PubMed  CAS  Google Scholar 

  • Charo, I. F., Ransohoff, R. M. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354(6):610–621.

    Article  PubMed  CAS  Google Scholar 

  • Chatenoud, L. (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3(2):123–132.

    Article  PubMed  CAS  Google Scholar 

  • Chen, B. J., Morris, R. E., Chao, N. J. (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol. Blood Marrow Transplant. 6(5A):529–536.

    Article  PubMed  CAS  Google Scholar 

  • Chiba, K. (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108(3):308–319.

    Article  PubMed  CAS  Google Scholar 

  • Clements, J. M., Cossins, J. A., Wells, G. M., et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74(1–2):85–94.

    Article  PubMed  CAS  Google Scholar 

  • Cohen, B. A., Mikol, D. D. (2004) Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63(Suppl. 6):S28–S32.

    PubMed  CAS  Google Scholar 

  • Coles, A. J., Wing, M. G., Molyneux, P., et al. (1999a) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46(3):296–304.

    Article  PubMed  CAS  Google Scholar 

  • Coles, A. J., Wing, M., Smith, S., et al. (1999b) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354(9191):1691–1695.

    Article  PubMed  CAS  Google Scholar 

  • Columba-Cabezas, S., Serafini, B., Ambrosini, E., et al. (2002) Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 130(1–2):10–21.

    Article  PubMed  CAS  Google Scholar 

  • Cyster, J. G. (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23:127–159.

    Article  PubMed  CAS  Google Scholar 

  • Dello Russo, C., Gavrilyuk, V., Weinberg, G., et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278(8):5828–5836.

    Article  PubMed  CAS  Google Scholar 

  • Diab, A., Deng, C., Smith, J. D., et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168(5):2508–2515.

    PubMed  CAS  Google Scholar 

  • Dinter, H., Tse, J., Halks-Miller, M., Asarnow, D., et al. (2004) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J. Neuroimmunol. 108(1–2):136–146.

    Google Scholar 

  • Dormandy, J. A., Charbonnel, B., Eckland, D. J., et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289.

    Article  PubMed  CAS  Google Scholar 

  • Ducray, F., Vukusic, S., Gignoux, L. (2004) Mycophenolate mofetil: an open-label study in 42 MS patients. Mult. Scler. 10(Suppl.):S263–S263.

    Google Scholar 

  • Dunn, S. E., Youssef, S., Goldstein, M. J., et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203:401–412.

    Article  PubMed  CAS  Google Scholar 

  • Dyke, H. J., Montana, J. G. (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Invest. Drugs. 11(1):1–13.

    Article  CAS  Google Scholar 

  • Edan, G. (2005) Immunosuppressive therapy in multiple sclerosis. Neurol. Sci. 26(Suppl.) 1:S18.

    Google Scholar 

  • Edan, G., Miller, D., Clanet, M., et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62(2):112–118.

    Article  PubMed  CAS  Google Scholar 

  • Elices, M. J. (2003) Natalizumab: Elan/Biogen. Curr. Opin. Invest. Drugs 4(11):1354–1362.

    CAS  Google Scholar 

  • Engelhardt, B., Ransohoff, R. M. (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26(9):485–495.

    Article  PubMed  CAS  Google Scholar 

  • Faria, A. M., Weiner, H. L. (2005) Oral tolerance. Immunol. Rev. 206:232–259.

    Article  PubMed  CAS  Google Scholar 

  • Farrell, R., Heaney, D., Giovannoni, G., (2005) Emerging therapies in multiple sclerosis. [Review] Expert. Opin. Emerg. Drugs 10(4):797–816.

    Article  PubMed  CAS  Google Scholar 

  • Feinstein, D. L., Galea, E., Gavrilyuk, V., et al. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51(6):694–702.

    Article  PubMed  CAS  Google Scholar 

  • Feng, J., Misu, T., Fujihara, K., et al. (2004) Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult. Scler. 10(5):494–498.

    Article  PubMed  CAS  Google Scholar 

  • Fernandez, O., Guerrero, M., Mayorga, C., et al. (2002) Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J. Neurol. 249(8):1058–1062.

    Article  PubMed  CAS  Google Scholar 

  • Filippi, M., Rovaris, M., Rice, G. P., et al. (2000a) The effect of cladribine on T(1) ‘black hole’ changes in progressive MS. J. Neurol Sci. 176(1):42–44.

    Article  PubMed  CAS  Google Scholar 

  • Filippi, M., Rovaris, M., Iannucci, G., et al. (2000b) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 12;55(11):1714–1718.

    Google Scholar 

  • Fontoura, P., Garren, H., Steinman, L. (2005) Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int. Rev. Immunol. 24(5–6):415–446.

    Article  PubMed  CAS  Google Scholar 

  • Fox, R. J., Ransohoff, R. M. (2004) New directions in MS therapeutics: vehicles of hope. Trends Immunol. 25(12):632–636.

    Article  PubMed  CAS  Google Scholar 

  • Francis, G., Evans, A., Panitch, H. (1997) MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann. Neurol. 42:467.

    Google Scholar 

  • Frauwirth, K. A., Thompson, C. B. (2002) Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3):295–299.

    PubMed  CAS  Google Scholar 

  • Frohman, E. M., Brannon, K., Racke, M. K., Hawker, K. (2004) Mycophenolate mofetil in multiple sclerosis. Clin. Neuropharmacol. 27(2):80–83.

    Article  PubMed  CAS  Google Scholar 

  • Frohman, E. M., Racke, M. K., Raine, C. S. (2006) Multiple sclerosis—the plaque and its pathogenesis. N. Engl. J. Med. 354(9):942–955.

    Article  PubMed  CAS  Google Scholar 

  • Fujimoto, T., Sakoda, S., Fujimura, H., Yanagihara, T. (1999) Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. 95(1–2):35–42.

    Article  PubMed  CAS  Google Scholar 

  • Fujino, M., Funeshima, N., Kitazawa, Y., et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305(1):70–77.

    Article  PubMed  CAS  Google Scholar 

  • Gaupp, S., Pitt, D., Kuziel, W. A., et al. (2003) Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am. J. Pathol. 162(1):139–150.

    PubMed  Google Scholar 

  • Gauthier, S. A., Buckle, G. J., Weiner, H. L. (2005) Immunosuppressive therapy for multiple sclerosis. Neurol. Clin. 23(1):247–272, viii-ix.

    Article  PubMed  Google Scholar 

  • Genovese, M. C., Becker, J. C., Schiff, M., et al. (2005) Abatacept for rheumatoid athritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11):1114–1123.

    Article  PubMed  CAS  Google Scholar 

  • Germain, R. N., Stefanova, I. (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17:467–522.

    Article  PubMed  CAS  Google Scholar 

  • Ghalie, R. G., Mauch, E., Edan, G., et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8(5):441–445.

    Article  PubMed  CAS  Google Scholar 

  • Giuliani, F., Fu, S. A., Metz, L. M., Yong, V. W. (2005a) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol. 165(1–2):83–91.

    Article  PubMed  CAS  Google Scholar 

  • Giuliani, F., Metz, L. M., Wilson, T., et al. (2005b) Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158(1–2):213–221.

    Article  PubMed  CAS  Google Scholar 

  • Gonsette, R. E. (2004) New immunosuppressants with potential implication in multiple sclerosis. J. Neurol. Sci. 223(1):87–93.

    Article  PubMed  CAS  Google Scholar 

  • Gonsette, R. E., Dubois, B. (2004) Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J. Neurol. Sci. 223(1):81–86. Erratum in: J. Neurol. Sci. 2005;235(1–2):79.

    Article  PubMed  CAS  Google Scholar 

  • Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., et al. (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178.

    PubMed  CAS  Google Scholar 

  • Goodkin, D. E., Rudick, R. A., VanderBrug Medendorp, S., et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37(1):30–40.

    Article  PubMed  CAS  Google Scholar 

  • Goodkin, D. E., Shulman, M., Winkelhake, J., et al. (2000) A phase I trial of solubilized DR2:MBP84–102 (AG284) in multiple sclerosis. Neurology 54(7):1414–1420.

    PubMed  CAS  Google Scholar 

  • Gordon, E. J., Myers, K. J., Dougherty, J. P., et al. (1995) Both anti-CD IIa (LFA-1) and anti-CD IIb (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 62(2):153–160.

    Article  PubMed  CAS  Google Scholar 

  • Grillo-Lopez, A. J. (2005). 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma. Semin. Oncol. 32(Suppl. 1):S44–S49.

    Article  PubMed  CAS  Google Scholar 

  • Haas, J., Hug, A., Viehover, A., et al. (2005) Reduced suppressive effect of CD4+CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35(11):3343–3352.

    Article  PubMed  CAS  Google Scholar 

  • Hafler, D. A., Slavik, J. M., Anderson, D. E., et al. (2005) Multiple sclerosis. Immunol. Rev. 204:208–231.

    Article  PubMed  CAS  Google Scholar 

  • Hartung, H. P., Kieseier, B. C. (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107(2):140–147.

    Article  PubMed  CAS  Google Scholar 

  • Hartung, H. P., Gonsette, R., König, N., et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025.

    Article  PubMed  Google Scholar 

  • Hauser, S. L., Hauser, S. L., Dawson, D. M., et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308(4):173–180.

    Article  PubMed  CAS  Google Scholar 

  • He, K, Zeng, L, Shi, G, et al. (1997) Bioactive compounds from Taiwania cryptomerioides. J. Nat. Prod. 60(1):38–40.

    Article  PubMed  CAS  Google Scholar 

  • Hemmer, B., Archelos, J. J., Hartung, H. P. (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3(4):291–301.

    Article  PubMed  CAS  Google Scholar 

  • Hohlfeld, R. (1997) Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 120:865–916.

    Article  PubMed  Google Scholar 

  • Hohlfeld, R, Wekerle, H. (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U S A 101(Suppl. 2):14599–14606.

    Article  PubMed  CAS  Google Scholar 

  • Hohlfeld, R., Wekerle, H. (2005) Drug insight: using monoclonal antibodies to treat multiple sclerosis: Nature Clinical Practice. Neurology 1:34–44.

    PubMed  CAS  Google Scholar 

  • Hohlfeld, R., Wiendl, H. (2001) The ups and downs of multiple sclerosis therapeutics. Ann. Neurol. 49:281–284.

    Article  PubMed  CAS  Google Scholar 

  • Howard, L. M., Miga, A. J., Vanderlugt, C. L., et al. (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103(2):281–290.

    Article  PubMed  CAS  Google Scholar 

  • Howard, L. M., Kohm, A. P., Castaneda, C. L., Miller S. D. (2005) Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr. Drug Targets Inflamm. Allergy 4(2):205–216.

    Article  PubMed  CAS  Google Scholar 

  • Huston, J. S., George, A. J. (2001) Engineered antibodies take center stage. Hum. Antibodies 10(3–4):127–142.

    PubMed  CAS  Google Scholar 

  • Jeffery, D. R. (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology. 63(Suppl. 6):S41–S46.

    PubMed  CAS  Google Scholar 

  • Jönsson, S., Andersson, G., Fex, T., et al. (2004) Synthesis and biological evaluation of new 1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 47(8):2075–2088.

    Article  PubMed  CAS  Google Scholar 

  • Jung, S., Zielasek, J., Kollner, G., et al. (1996) Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68(1–2):1–11.

    Article  PubMed  CAS  Google Scholar 

  • Kappos, L., Patzold, U., Dommasch, D., et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis—results of the German multicenter study. Ann. Neurol. 23(1):56–63.

    Article  PubMed  CAS  Google Scholar 

  • Kappos, L., Comi, G., Panitch, H., et al. (2000). Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial: the Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6(10):1176–1182.

    Article  PubMed  CAS  Google Scholar 

  • Kappos, L., Radu, E. W., Antel, J., et al. (2005a) Promising results with a novel oral immunomodulator-FTY720-in relapsing multiple sclerosis. Mult. Scler. 11(Suppl.): S13.

    Google Scholar 

  • Kappos, L., Barkhof, F., Desmet, A. (2005b) The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J. Neurol. 252(Suppl. 2):46.

    Google Scholar 

  • Kappos, L., Antel, J., Comi, G., et al. (2006) Oral fingolimod (FTY720) for releasing multiple sclerosis. N. Engl. J. Med. 355(11):1124–1140.

    Article  PubMed  CAS  Google Scholar 

  • Karussis, D. M., Meiner, Z., Lehmann, D., et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47(2):341–346.

    PubMed  CAS  Google Scholar 

  • Kawai, T., Andrews, D., Colvin, R. B., et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6(2):114.

    Article  CAS  Google Scholar 

  • Keegan, M., Pineda, A. A., McClelland, R. L., et al. (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58(1):143–146.

    PubMed  CAS  Google Scholar 

  • Keegan, M., Konig, F., McClelland, R., et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579–582.

    Article  PubMed  Google Scholar 

  • Keeley, K. A., Rivey, M. P., Allington, D. R. (2005) Natalizumab for the treatment of multiple sclerosis and Crohn’s disease. Ann. Pharmacother. 39(11):1833–1843.

    Article  PubMed  CAS  Google Scholar 

  • Keir, M. E., Sharpe, A. H. (2005) The B7/CD28 costimulatory family in autoimmunity. Immunol. Rev. 204:128–143.

    Article  PubMed  CAS  Google Scholar 

  • Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352(25):2598–2608.

    Article  PubMed  CAS  Google Scholar 

  • Kieseier, B. C., Kiefer, R., Clements, J. M., et al. (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1):159–166.

    Article  PubMed  Google Scholar 

  • Kieseier, B. C., Seifert, T., Giovannoni, G., Hartung, H. P. (1999) Matrix metallo-proteinases in inflammatory demyelination: targets for treatment. Neurology 53(1):20–25.

    PubMed  CAS  Google Scholar 

  • Khoury, J., Viglietta, V., Buckle, G., et al. (2005) Neurology 64(Suppl. 1):A393, S46.004.

    Google Scholar 

  • Kim, K. S., Jacob, N., Stohl, W. (2003) In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin. Immunol. 108(3):182–189.

    Article  PubMed  CAS  Google Scholar 

  • Kleinschmidt-DeMasters, B. K., Tyler, K. L. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353(4):369–374.

    Article  PubMed  CAS  Google Scholar 

  • Klotz, L., Schmidt, M., Giese, T., et al. (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175(8):4948–4955.

    PubMed  CAS  Google Scholar 

  • Kobata, T., Azuma, M., Yagita, H., Okumura, K. (2000) Role of costimulatory molecules in autoimmunity. Rev. Immunogenet. 2(1):74–80.

    PubMed  CAS  Google Scholar 

  • Kohm, A. P., Williams, J. S., Bickford, A. L., et al. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174(8):4525–4534.

    PubMed  CAS  Google Scholar 

  • Korn, T., Toyka K., Hartung, H. P., Jung, S. (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124(Pt 9):1791–1802.

    Article  PubMed  CAS  Google Scholar 

  • Korn, T., Magnus, T., Toyka, K., Jung, S. (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide—mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 76(5):950–960.

    Article  PubMed  CAS  Google Scholar 

  • Kwak, B., Mulhaupt, F., Myit, S., Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6(12):1399–1402.

    Article  PubMed  CAS  Google Scholar 

  • Lang, H. L., Jacobsen, H., Ikemizu, S. (2002) Nat. Immunol. 3:940–943.

    Article  PubMed  CAS  Google Scholar 

  • Langer-Gould, A., Atlas, S. W., Green, A. J., et al. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353(4):375–381.

    Article  PubMed  CAS  Google Scholar 

  • Larsen, C. P., Knechtle, S. J., Adams, A., et al. (2006) A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6(5):876–883.

    Article  PubMed  CAS  Google Scholar 

  • Lassmann, H., Bruck, W., Lucchinetti, C. (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 14:259–269.

    Google Scholar 

  • Lebwohl, M., Tyring, S. K., Hamilton, T. K., et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349(21):2004–2013.

    Article  PubMed  CAS  Google Scholar 

  • Lennon, V. A., Kryzer, T. J., Pittock, S. J., et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202(4):473–477.

    Article  PubMed  CAS  Google Scholar 

  • Li, B., Wang, H., Dai, J., et al. (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116(4):487–498.

    PubMed  CAS  Google Scholar 

  • Likosky, W. H., Fireman, B., Elmore, R., et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J. Neurol. Neurosurg. Psychiatry. 54(12):1055–1060.

    Article  PubMed  CAS  Google Scholar 

  • Lindberg, R. L., De Groot, C. J., Montagne, L., et al. (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Pt 9):1743–1753.

    Article  PubMed  CAS  Google Scholar 

  • Lindsey, J. W., Hodgkinson, S., Mehta, R., et al. (1994a) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36(2):183–189.

    Article  PubMed  CAS  Google Scholar 

  • Lindsey, J. W., Hodgkinson, S., Mehta, R., et al. (1994b) Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 44(Pt 1):413–419.

    PubMed  CAS  Google Scholar 

  • Linsley, P. S., Brady, W., Urnes, M., et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3):561–569.

    Article  PubMed  CAS  Google Scholar 

  • Llewellyn-Smith, N., Lai, M., Miller, D. H., et al. (1997) Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 48(4):810–816.

    PubMed  CAS  Google Scholar 

  • Lovett-Racke, A. E., Bittner, P., Cross, A. H., et al. (1998) Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J. Clin. Invest. 101(8):1797–1804.

    Article  PubMed  CAS  Google Scholar 

  • Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., et al. (2004) Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172(9):5790–5798.

    PubMed  CAS  Google Scholar 

  • Lublin, F., et al. (1999) A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of MS [abstract 290]. Neurology 52, Suppl 2.

    Google Scholar 

  • Lucchinetti, C., Bruck, W., Parisi, J., et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6):707–717.

    Article  PubMed  CAS  Google Scholar 

  • Lucchinetti, C. F., Mandler, R. N., McGavern, D., et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461.

    Article  PubMed  Google Scholar 

  • Lus, G., Romano, F., Scuotto, A., et al. (2004) Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol. 51(1):15–20.

    Article  PubMed  CAS  Google Scholar 

  • Maeda, A., Sobel, R. A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55(3):300–309.

    Article  PubMed  CAS  Google Scholar 

  • Mandala, S., Hajdo, R., Bergstrom, J., et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566): 346–349.

    Article  PubMed  CAS  Google Scholar 

  • Marecki, S., Kirkpatrick, P. (2004) Efalizumab. Nat. Rev. Drug Discov. 3(6):473–474.

    Article  PubMed  CAS  Google Scholar 

  • Markovic-Plese, S., Bielekova, B., Kadom, N., et al. (2003) Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 60(11):1849–1851.

    PubMed  CAS  Google Scholar 

  • Marracci, G. H., McKeon, G. P., Marquardt, W. E., et al. (2004) Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res. 78(3):362–370.

    Article  PubMed  CAS  Google Scholar 

  • Marracci, G. H., Shinto, L., Strehlow, A., et al. (2005) Effect of omega-3 fatty acid supplementation on matrix metalloproteinase-9 production in multiple sclerosis. Neurology 64(Suppl. 1):A192–A193, P03.119.

    Google Scholar 

  • Massacesi, L., Parigi, A., Barilaro, A., et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol. 62(12):1843–7.

    Article  PubMed  Google Scholar 

  • Matloubian, M., Lo, C.G., Cinamon, G., et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427(6972):355–60.

    Article  PubMed  CAS  Google Scholar 

  • Maurer, M., Loserth S., Kolb-Maurer A., et al. (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics. 54(1):1–8. Epub 2002 Mar 12.

    Article  PubMed  CAS  Google Scholar 

  • Meden, H., Mielke S., Marx D., et al. (1997) Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res. 17(4B):3075–7.

    PubMed  CAS  Google Scholar 

  • Menge, T., Hartung, H. P., Stüve, O. (2005) Statins-a cure-all for the brain? Nat Rev Neurosci. 6(4):325–31.

    Article  PubMed  CAS  Google Scholar 

  • Metz, L. M., Zhang, Y., Yeung, M., et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 55(5):756.

    Article  PubMed  Google Scholar 

  • Miller, D. H., Khan, O. A., Sheremata, W. A., et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 348(1):15–23.

    Article  PubMed  CAS  Google Scholar 

  • Monson, N. L., Cravens, P. D., Frohman, E. M., et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 62(2):258–64.

    Article  PubMed  Google Scholar 

  • Morini, M., Roccatagliata, L., Dell’Eva, R., et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148(1–2):146–153.

    Article  PubMed  CAS  Google Scholar 

  • Muller, H., Hofer, S., Kaneider, N., et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. 35(2):533–545.

    Article  PubMed  CAS  Google Scholar 

  • Multiple Sclerosis Study Group. (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann. Neurol. 27(6):591–605.

    Article  Google Scholar 

  • Nakajima, A., Yamanaka, H., Kamatani, N. (2003) Leflunomide: clinical effectiveness and mechanism of action. Clin. Calcium 13(6):771–775.

    PubMed  CAS  Google Scholar 

  • Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59(7):990–997.

    PubMed  CAS  Google Scholar 

  • Nicholson, L. B., Greer, J. M., Sobel, R. A., et al. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3(4):397–405.

    Article  PubMed  CAS  Google Scholar 

  • Niino, M., Kikuchi, S., Fukazawa, T., et al. (2001) Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 118(2):295–299.

    Article  PubMed  CAS  Google Scholar 

  • Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G. (2000a) Multiple sclerosis. N. Engl. J. Med. 343:938–952.

    Article  PubMed  CAS  Google Scholar 

  • Noseworthy, J. H., Wolinsky, J. S., Lublin, F. D., et al. (2000b) Linomide in relapsing and secondary progressive MS. I. Trial design and clinical results; North American Linomide Investigators. Neurology 2000;54(9):1726–1733.

    PubMed  CAS  Google Scholar 

  • Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G. (2001) Multiple Sclerosis. N. Engl. J. Med. 343(13):938–952.

    Article  Google Scholar 

  • O’Connor, P. W., Li, D., Freedman, M. S., et al. (2006a) Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group: a phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66(6):894–900.

    Article  PubMed  CAS  Google Scholar 

  • O’Connor, P., Antel, J., Comi, G. (2006b) Oral FTY720 in relapsing MS: results of the dose-blinded, active drug extension phase of a phase II study. Neurology 66(Suppl. 5):A123.

    Google Scholar 

  • Omari, K. M., John, G. R., Sealfon, S. C., Raine, C. S. (2005) CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 128(Pt 5):1003–1015.

    Article  PubMed  Google Scholar 

  • Omari, K. M., John, G., Lango, R., Raine, C. S. (2006) Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53(1):24–31.

    Article  PubMed  Google Scholar 

  • Paemen, L., Martens, E., Norga, K., et al. (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. 52(1):105–111.

    Article  PubMed  CAS  Google Scholar 

  • Paintlia, A. S., Paintlia, M. K., Khan, M., et al. (2005) HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 19(11):1407–1421.

    Article  PubMed  CAS  Google Scholar 

  • Palace, J., Rothwell, P. (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350(9073):261.

    Article  PubMed  CAS  Google Scholar 

  • Panitch, H., Francis, G., Oral Myelin Study Group. (1997) Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann. Neurol. 42:459.

    Google Scholar 

  • Paolillo, A., Coles, A. J., Molyneux, P. D., et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53(4):751–757.

    PubMed  CAS  Google Scholar 

  • Patti, F., Amato, M. P., Filippi, M., et al. (2004) A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J. Neurol. Sci. 223(1):69–71.

    Article  PubMed  CAS  Google Scholar 

  • Pershadsingh, H. A. (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Invest. Drugs 13(3): 215–228.

    Article  CAS  Google Scholar 

  • Pershadsingh, H. A., Heneka, M. T., Saini, R., et al. (2004) Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflamm. 1(1):3.

    Article  Google Scholar 

  • Petereit, H. F., Rubbert, A. (2005) Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch. Neurol. 62(10):1641–1642; author reply 1642.

    Article  PubMed  Google Scholar 

  • Polman, C., Barkhof, F., Sandberg-Wollheim, M., et al. (2005) Laquinimod in Relapsing MS Study Group: Treatment with laquinimod reduces development of active I lesions in relapsing MS. Neurology 64(6):987–991.

    PubMed  CAS  Google Scholar 

  • Polman, C. H., O’Connor, P. W., Havrdova, E., et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9):899–910.

    Article  PubMed  CAS  Google Scholar 

  • Popovic, N., Schubart, A., Goetz, B. D., et al. (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51(2):215–223.

    Article  PubMed  CAS  Google Scholar 

  • Ramtahal, J., Jacob, A., Das, K., Boggild, M. (2005) 5-Year retrospective study of the use of mitoxantrone and glatiramer acetate combination in Patients with very active relapsing remitting multiple sclerosis. Neurology 4(Suppl. 1):A386–387, P06.163.

    Google Scholar 

  • Ransohoff, R. M. (1999) Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J. Neuroimmunol. 98(1):57–68.

    Article  PubMed  CAS  Google Scholar 

  • Ransohoff, R. M. (2005) Natalizumab and PML. Nat. Neurosci. 8(10):1275.

    Article  PubMed  CAS  Google Scholar 

  • Rausch, M., Hiestand, P., Foster, C. A., et al. (2004) Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20(1):16–24.

    Article  PubMed  Google Scholar 

  • Reggio, E., Nicoletti, A., Fiorilla, T. (2005) The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: twenty-four months follow-up. J. Neurol. 252(10):1255–1261.

    Article  PubMed  CAS  Google Scholar 

  • Rice, G. P., Filippi M., Comi G. (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial: Cladribine MRI Study Group. Neurology 14;54(5):1145–1155.

    Google Scholar 

  • Rice G. P, Hartung, H. P., Calabresi, P. A. (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336–1342.

    PubMed  CAS  Google Scholar 

  • Rizvi, S. A., Bashir, K. (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63(Suppl. 6):S47–S54.

    PubMed  CAS  Google Scholar 

  • Romine, J. S., Sipe, J. C., Koziol, J. A., et al. (1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111(1):35–44.

    Article  PubMed  CAS  Google Scholar 

  • Rose, J. W., Watt, H. E., White, A. T., Carlson, N. G. (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56(6): 864–867.

    Article  PubMed  CAS  Google Scholar 

  • Rosen, H., Goetzl, E.J (2005) Spingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5(7):560–570.

    Article  PubMed  CAS  Google Scholar 

  • Rudick, R. A., Stuart, W. H., Calabresi, P. A., et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354(9):911–923.

    Article  PubMed  CAS  Google Scholar 

  • Rumbach, L., Racadot, E., Armspach, J. P., et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult. Scler. 1(4):207–212.

    PubMed  CAS  Google Scholar 

  • Runstrom, A., Leanderson, T., Ohlsson, L., Axelsson, B. (2006) Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J. Neuroimmunol. 173(1–2):69–78.

    Article  PubMed  CAS  Google Scholar 

  • Sakaguchi, S. (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4):345–352.

    Article  PubMed  CAS  Google Scholar 

  • Salomon, B., Bluestone, J. A. (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225–252.

    Article  PubMed  CAS  Google Scholar 

  • Scheinfeld, N. (2006) Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin. Drug Saf. 5(2):197–209.

    Article  PubMed  CAS  Google Scholar 

  • Schimrigk, K., Brune, N., Hellwig, K., et al. (2005) An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Neurology. 64(Suppl. 1):A392, S46.003.

    Google Scholar 

  • Scolding, N. (2005) Devic’s disease and autoantibodies. Lancet Neurol. 4(3):136–137.

    PubMed  Google Scholar 

  • Scott, G. S., Spitsin, S. V., Kean, R. B., et al. (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. U S A. 99(25):16303–16308.

    Article  PubMed  CAS  Google Scholar 

  • Sehgal, S. N. (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35(Suppl):7S–14S.

    Article  PubMed  CAS  Google Scholar 

  • Sellebjerg, F., Sorensen, T. L. (2003) Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 61(3):347–355.

    Article  PubMed  CAS  Google Scholar 

  • Serkova, N. J., Christians, U., Benet, L. Z. (2004) Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. 4(2):97–107.

    Article  PubMed  CAS  Google Scholar 

  • Sette, A., Alexander, J., Ruppert, J., et al. (1994) Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu. Rev. Immunol. 12:413–431.

    Article  PubMed  CAS  Google Scholar 

  • Sharpe, A. H., Freeman, G. J. (2002) The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2):116–126.

    Article  PubMed  CAS  Google Scholar 

  • Sicotte, N. L., Liva, S. M., Klutch, R., et al. (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52(4):421–428.

    Article  PubMed  CAS  Google Scholar 

  • Sicotte, N. L., Giesser, B. S., Tandon, V. (2006) A pilot study of testosterone treatment for men with relapsing remitting multiple sclerosis. Neurology 66(Suppl.):A30–A30.

    Google Scholar 

  • Sidiropoulos, P. I., Boumpas, D. T. (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5):391–397.

    Article  PubMed  CAS  Google Scholar 

  • Simmons, D. L., Buckley, C. D. (2005) Some new, and not so new, anti-inflammatory targets. Curr. Opin. Pharmacol. 5(4):394–397.

    Article  CAS  Google Scholar 

  • Sipe, J. C. (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. 5(6):721–727.

    Article  PubMed  CAS  Google Scholar 

  • Sipe, J. C., Romine, J. S., Koziol, J. A., et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344(8914):9–13.

    Article  PubMed  CAS  Google Scholar 

  • Sipe, J. C., Romine, J. S., Koziol, J., et al. (1997) Cladribine improves relapsing-remitting MS: a double blind placebo controlled study. Neurology 48(Suppl. 2):A340.

    Google Scholar 

  • Sjöö, F., Hassan Z., Abedi-Valugerdi, M., et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol. 34(1):115–121.

    Article  PubMed  CAS  Google Scholar 

  • Smilek, D. E., Wraith, D. C., Hodgkinson, S., et al. (1991). A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U S A 88(21):9633–9637.

    Article  PubMed  CAS  Google Scholar 

  • Smolen, J. S., Emery, P., Kalden, J. R., et al. (2004) The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J. Rheumatol. Suppl. 71:13–20.

    CAS  Google Scholar 

  • Sommer, N., Loschmann, P. A., Northoff, G. H., et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1(3):244–248.

    Article  PubMed  CAS  Google Scholar 

  • Sorensen, T. L., Tani, M., Jensen, J., et al. (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103(6):807–815.

    Article  PubMed  CAS  Google Scholar 

  • Sorensen, T. L., Trebst, C., Kivisakk, P., et al. (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127(1–2):59–68.

    Article  PubMed  CAS  Google Scholar 

  • Sospedra, M., Martin, R. (2005a) Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683–747.

    Article  PubMed  CAS  Google Scholar 

  • Sospedra, M., Martin, R. (2005b) Antigen-specific therapies in multiple sclerosis. Int. Rev. Immunol. 24(5–6):393–413.

    Article  PubMed  CAS  Google Scholar 

  • Steinman, L. (2001) Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:762–764.

    Article  PubMed  CAS  Google Scholar 

  • Steinman, L. (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6):510–518.

    Article  PubMed  CAS  Google Scholar 

  • Steinman, L., Zamvil, S. S. (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26(11):565–571.

    Article  PubMed  CAS  Google Scholar 

  • Storer, P. D, Xu, J., Chavis, J., Drew, P. D. (2005). Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161(1–2):113–122.

    Article  PubMed  CAS  Google Scholar 

  • Stuart, R. W., Racke, M. K. (2002) Targeting T cell costimulation in autoimmune disease. Expert Opin. Ther. Targets. 6(3):275–289.

    Article  PubMed  CAS  Google Scholar 

  • Stüve, O., Cepok, S., Elias, B., et al. (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62(10):1620–1623.

    Article  PubMed  Google Scholar 

  • Stüve, O., Youssef, S., Weber, M.S., et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest. 116:1037–1044.

    Article  PubMed  CAS  Google Scholar 

  • Swain, S. M. (1998) Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin. Oncol. 25(Suppl. 10):43–47.

    PubMed  CAS  Google Scholar 

  • Tubridy, N., Behan, P. O., Capildeo, R., et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS; the UK Antegren Study Group. Neurology 53(3):466–472.

    PubMed  CAS  Google Scholar 

  • Ubogu, E. E., Cossoy, M. B., Ransohoff, R. M. (2005) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27(1):48–55.

    Article  PubMed  CAS  Google Scholar 

  • Utset, T. O., Auger, J. A., Peace, D., et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29(9):1907–1913.

    PubMed  CAS  Google Scholar 

  • Van Assche, G., Van Ranst, M., Sciot, R., et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353(4): 362–368.

    Article  PubMed  Google Scholar 

  • Van Oosten, B. W., Uitdehaag, B. M., Barkhof, F., et al. (1997) Interleukin-2 therapy does not exacerbate multiple sclerosis. Neurology 49(2):633–634.

    PubMed  Google Scholar 

  • Vermersch, P., Waucquier, N., Bourteel, H., et al. (2004) Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept): results of a phase II clinical trial. Neurology 62(Suppl.):A259–A259.

    Google Scholar 

  • Viglietta, V., Baecher-Allan, C., Weiner, H. L., Hafler, D. A. (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199(7):971–979.

    Article  PubMed  CAS  Google Scholar 

  • Vincenti, F., Kirkman, R., Light, S., et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338(3):161–165.

    Article  PubMed  CAS  Google Scholar 

  • Vollmer, T., Key, L., Durkalski, V., et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363(9421):1607–1608.

    Article  PubMed  CAS  Google Scholar 

  • Waldmann, H. (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu. Rev. Immunol. 7:407–444.

    Article  PubMed  CAS  Google Scholar 

  • Warren, K. G., Catz, I., Wucherpfennig, K. W. (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152(1):31–38.

    Article  PubMed  CAS  Google Scholar 

  • Webb, M., Tham, C. S., Lin, F. F., et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153(1–2):108–121.

    Article  PubMed  CAS  Google Scholar 

  • Weber, M. S., Prod’homme, T., Steinman, L., Zamvil, S. S. (2005) Drug Insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol. 1:106–112.

    Article  PubMed  CAS  Google Scholar 

  • Wei, S. H., Rosen, H., Matheu, M. P., et al. (2005) Shingosine-1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol. 6(12):1228–1235.

    Article  PubMed  CAS  Google Scholar 

  • Weiner, H. L., Cohen, J. A. (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8(2):142–154.

    Article  PubMed  CAS  Google Scholar 

  • Weiner, H. L., Mackin, G. A., Matsui, M., et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259(5099):1321–1324.

    Article  PubMed  CAS  Google Scholar 

  • Weinshenker, B. G., Bass, B., Karlik, S., et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41(7):1047–1052.

    PubMed  CAS  Google Scholar 

  • Weissert, R., Wiendl, H., Pfrommer, H., et al. (2003) Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J. Neuroimmunol. 144(1–2):28–37.

    Article  PubMed  CAS  Google Scholar 

  • Wiendl, H., Hohlfeld, R. (2002). Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 16(3):183–200.

    Article  PubMed  CAS  Google Scholar 

  • Wiendl, H., Hohlfeld, R. (2006) Cytokine-based therapeutics for intrinsic CNS disease processes. In Ransohoff R. M., Benveniste E. N. (Eds): Cytokines and the CNS, Taylor & Francis, 2nd Edition, 328–351.

    Google Scholar 

  • Wiendl, H., Kieseier, B. C., Weissert, R., et al. (2005) Treatment of active secondary progressive multiple sclerosis with treosulfan: an open label pilot study. Mult. Scler. 11(Suppl.1):181, P680.

    Google Scholar 

  • Willenborg, D. O., Fordham, S., Bernard, C. C., et al. (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157(8):3223–3227.

    PubMed  CAS  Google Scholar 

  • Wingerchuk, D. M., Weinshenker, B. G. (2005) Neuromyelitis optica. Curr. Treat. Options Neurol. 7(3):173–182.

    Article  PubMed  Google Scholar 

  • Yadav, V., Marracci, G., Lovera, J., et al. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. 11(2):159–165.

    Article  PubMed  CAS  Google Scholar 

  • Yang, J. S., Xu, L. Y., Xiao, B. G., et al. (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156(1–2):3–9.

    Article  PubMed  CAS  Google Scholar 

  • Yong, V. W. (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6(12):931–944.

    Article  PubMed  CAS  Google Scholar 

  • Yong, V. W., Wells, J., Giuliani, F., et al. (2004) The promise of minocycline in neurology. Lancet Neurol. 3(12):744–751.

    Article  PubMed  Google Scholar 

  • Yopp, A. C., Fu, S., Honig, S. M., et al. (2004) FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol. 173(2):855–865.

    PubMed  CAS  Google Scholar 

  • Yousry, T. A., Major, E. O., Ryschkewitsch, C., et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9):924–933.

    Article  PubMed  CAS  Google Scholar 

  • Youssef, S., Stuve, O., Patarroyo, J. C., et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78–84.

    Article  PubMed  CAS  Google Scholar 

  • Yudkin, P. L., Ellison, G. W., Ghezzi, A., et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338(8774):1051–1055.

    Article  PubMed  CAS  Google Scholar 

  • Zhao, G. J., Li, D. K., Wolinsky, J. S., et al. (1997) Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis; the MS Study Group. J. Neuroimaging 7(1):1–7.

    PubMed  CAS  Google Scholar 

  • Zipp, F., Krammer, P. H., Weller, M. (1999) Immune (dys) regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol. Today 20:550–554.

    Article  PubMed  CAS  Google Scholar 

  • Zipp, F., Hartung, H. P., Hillert, J., et al. (2005). Blockade of chemokine receptor in multiple sclerosis patients. Mult. Scler. 11(Suppl. 1):S13.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Wuerzburg, Wuerzburg, Germany

    Heinz Wiendl

  2. Department of Neuroimmunology, Max Planck-Institute for Neurobiology, Martinsried, Germany

    Reinhard Hohlfeld

Authors
  1. Heinz Wiendl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reinhard Hohlfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Shanghai JiaoTong University School of Medicine, Shanghai, China

    Jingwu Zhang M.D., Ph.D.

  2. Baylor College of Medicine, Houston, Texas, USA

    Jingwu Zhang M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wiendl, H., Hohlfeld, R. (2007). Review of Novel Immunotherapeutic Strategies for MS. In: Zhang, J. (eds) Immune Regulation and Immunotherapy in Autoimmune Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-36003-4_14

Download citation

Publish with us

Policies and ethics

Search

Navigation